www.ip-watch.org

www.ip-watch.org
Share

www.ip-watch.org

 •  May 30

What if you get an aggressive form of breast cancer, and the treatment exists but it is too expensive for you to get? You die. Tragic stories and the possibilities to avert them were centre stage at a panel last week on the margin of the ongoing World Health Assembly. Delinking the cost of research and development from the market prices of...

www.ip-watch.org

 •  May 18

It appears not just unfair, but absurdly so. The US government paid for research that produced a patented drug, the patents were licensed exclusively to a Japanese firm, and that firm is now committing price discrimination against the US. Astellas Pharma is selling its anti-prostate cancer drug, Xtandi, for over $129,000 per year per patient in the...

www.ip-watch.org

 •  February 14

The European Commission has issued a working document in which they identify policy areas to support the long-term sustainability of the pharmaceutical sector. The document [pdf], titled “Pharmaceutical Industry: A Strategic Sector for the European Economy, ” underlines the importance of intellectual property rights for the sector. It also “focuses...